Key Points {#FPar1}
==========

Benralizumab is a targeted therapy approved as add-on maintenance treatment for patients aged 12 years and older with uncontrolled asthma and inflammation associated with eosinophils, a type of white blood cell.Analysis of pooled pharmacokinetic (PK) data of benralizumab from nine phase I--III clinical trials demonstrated that the PK of benralizumab were consistently dose-proportional across a dosage range of 0.03--3 mg/kg intravenously and 2--200 mg subcutaneously every 4 weeks or every 8 weeks (first three doses every 4 weeks). The elimination half-life of benralizumab was approximately 15.5 days for patients with asthma.Body weight and the presence of antidrug antibodies were the only variables that had an impact on the PK of benralizumab.

Introduction {#Sec1}
============

Eosinophilic inflammation, an important element of asthma pathogenesis, is associated with increased disease severity and exacerbations, decreased lung function, and increased mortality for patients with asthma \[[@CR1]--[@CR4]\]. Benralizumab is an interleukin-5 receptor (IL-5R) alpha--directed cytolytic monoclonal antibody (mAb) that depletes eosinophils by enhanced antibody-dependent cell-mediated cytotoxicity \[[@CR5]\]. It was recently approved as add-on maintenance treatment for patients with severe asthma aged 12 years and older and with an eosinophilic phenotype \[[@CR6]--[@CR8]\].

Pharmacokinetic (PK) and blood eosinophil count data from early stage clinical studies were modeled to facilitate selection of optimal dose levels and dosing schedule of benralizumab for a phase IIb proof-of-concept study for adult patients with severe asthma \[[@CR9], [@CR10]\]. Subsequently, two dosing regimens of benralizumab 30 mg (every 4 weeks, or every 4 weeks for the first three doses followed by every 8 weeks) were selected for the following phase III trials: SIROCCO \[[@CR11]\] and CALIMA \[[@CR12]\], which evaluated the effect of benralizumab on the rate of annual asthma exacerbation; ZONDA \[[@CR13]\], an oral corticosteroid (OCS) reduction study; and BISE \[[@CR14]\], a pulmonary function study. SIROCCO and CALIMA reported that benralizumab 30 mg every 4 weeks or every 8 weeks significantly reduced asthma exacerbation rates and increased forced expiratory volume in 1 s (FEV~1~) for patients with severe asthma receiving high-dosage inhaled corticosteroids/long-acting β~2~-agonists with baseline blood eosinophil counts ≥ 300 cells/µL \[[@CR11], [@CR12]\]. Subsequent population modeling analyses of pooled data from SIROCCO and CALIMA confirmed that 30 mg every 8 weeks, with an additional dose at week 4, is the optimal dosage of benralizumab for the treatment of patients with severe asthma \[[@CR15]\].

The aims of this investigation were to characterize the PK of benralizumab in adults and adolescents with severe, eosinophilic asthma using a population approach, and to evaluate the potential effects of demographic covariates and concomitant medication use on PK exposure of benralizumab in this population.

Methods {#Sec2}
=======

Ethics Approval {#Sec3}
---------------

All clinical study protocols and patient consent documents were reviewed by the local Institutional Review Board (IRB), and written IRB approvals were obtained prior to the initiation of each study.

All clinical studies were conducted in accordance with the ethical principles described in the Declaration of Helsinki, the International Conference on Harmonisation Guidance for Good Clinical Practice, any applicable regulatory requirements, and any conditions required by a regulatory authority and/or IRB.

Study Population {#Sec4}
----------------

Five phase I and II clinical studies (NCT00512486 \[[@CR16]\], NCT00659659 \[[@CR17]\], NCT00768079 \[[@CR18]\], NCT00783289 \[[@CR19]\], NCT01238861 \[[@CR9]\]) were conducted in adult patients with asthma. Four phase III studies (SIROCCO \[NCT01928771\] \[[@CR11]\], CALIMA \[NCT01914757\] \[[@CR12]\], BISE \[NCT02322775\] \[[@CR14]\], and ZONDA \[NCT02075255\] \[[@CR13]\]) were conducted in adults and adolescents with severe asthma.

Dosing and Sampling Schedule {#Sec5}
----------------------------

Patients with asthma received either intravenous or subcutaneous benralizumab. In phase I and II studies, single doses of 0.0003--3 mg/kg were administered by intravenous infusion. Subcutaneous dosages ranging from 2 to 200 mg were administered every 4 weeks or every 8 weeks. In the phase III studies, benralizumab was administered at 30 mg subcutaneously every 4 weeks, or 30 mg subcutaneously every 8 weeks. Table [1](#Tab1){ref-type="table"} lists the study designs, number of patients, and PK sampling schedules.Table 1Summary of clinical studies included in the population pharmacokinetic analysisStudy numberStudy type and designStudy populationDosage(s) of benralizumabRouteFrequency of administrationOverall objectivesNCT00512486 \[[@CR16]\]Phase I; OL/DEM and F; 18--45 years of age; mild atopic asthma; 44 RP0.03, 0.1, 0.3, 1.0, 3.0, 0.003, and 0.0003 mg/kgIVSingle doseSafetyNCT00659659 \[[@CR17]\]Phase I; RD/DB/PC/DEM and F; 18--65 years of age; asthma; ≥ 2.5% of eosinophils in sputum; 27 RP1.0 mg/kg100 and 200 mgIVSCSingle doseQ4W for 8 weeksSafety and tolerabilityNCT00768079 \[[@CR18]\]Phase II; RD/DB/PCM and F; 18--60 years of age; ≥ 2 years of asthma; asthma exacerbation requiring urgent care in the year prior to screening; 110 RP0.3 or 1.0 mg/kgIVSingle doseSafety and efficacyNCT00783289 \[[@CR19]\]Phase II; RD/DB/PC/DEM and F; 18--80 years of age; asthma; 25 RP25, 100, or 200 mgSCQ4W for 8 weeksSafety and tolerabilityNCT01238861 \[[@CR9]\]Phase II; RD/DB/PC/DRM and F; 18--75 years of age; asthma; medium- or high-dosage ICS/LABA; 609 RP2, 20, or 100 mgSCQ4W for 8 weeks, then Q8W for 32 weeksSafety and efficacySIROCCO (NCT01928771) \[[@CR11]\]Phase III; RD/DB/PCM and F; 12--75 years of age; uncontrolled asthma; high-dosage ICS/LABA; 1205 RP30 mg30 mgSCSCQ4W for 44 weeksQ4W for 8 weeks, then Q8W for 32 weeksSafety and efficacyCALIMA (NCT01914757) \[[@CR12]\]Phase III; RD/DB/PCM and F; 12--75 years of age; uncontrolled asthma; mid- or high-dosage ICS/LABA; 1306 RP30 mg30 mgSCSCQ4W for 52 weeksQ4W for 8 weeks, then Q8W for 40 weeksSafety and efficacyZONDA (NCT02075255) \[[@CR13]\]Phase III; RD/DB/PCM and F; 18--75 years of age; uncontrolled asthma; high-dosage ICS/LABA and long-term oral corticosteroid therapy; 220 RP30 mg30 mgSCSCQ4W for 24 weeksQ4W for 8 weeks, then Q8W for 16 weeksSafety and efficacyBISE (NCT02322775) \[[@CR14]\]Phase III; RD/DB/PCM and F; 18--75 years of age; mild to moderate persistent asthma; 211 RP30 mgSC3 doses at weeks 0, 4, and 8Safety and efficacy*DB* double-blind, *DE* dose escalation, *DR* dose ranging, *F* female, *ICS* inhaled corticosteroids, *IV* intravenous, *LABA* long-acting β~2~-agonist, *M* male, *OL* open label, *PC* placebo-controlled, *Q4W* every 4 weeks, *Q8W* every 8 weeks, *RD* randomized, *RP* randomized patients, *SC* subcutaneous

Bioanalysis {#Sec6}
-----------

We determined plasma or serum concentrations of benralizumab using validated immunoassays. Noncompeting anti-benralizumab idiotype antibodies were used as capturing and detecting reagents. For study NCT00512486, we measured benralizumab plasma concentrations with a validated enzyme-linked immunoassay method with a lower limit of quantification (LLOQ) of 60 ng/mL. For the other studies, benralizumab concentrations in serum (or plasma for study NCT00659659) were determined using a validated electrochemiluminescent sandwich immunoassay that employed Meso Scale Discovery (Rockville, MD, USA) technology, with an LLOQ of 3.86 ng/mL.

Pharmacokinetic (PK) Data Analysis {#Sec7}
----------------------------------

### Data Handling and Exclusions {#Sec8}

The PK and demographic covariate data from each study were formatted into derived population analysis datasets using SAS 9.3 (SAS Institute Inc, Cary, NC, USA). We excluded PK concentration outliers with no mechanistic explanation for their deviations from the analysis (a priori outliers). Outliers based on the population PK model analysis (a posteriori outliers) were evaluated using conditional weighted residuals (CWRES) and individual weighted residuals (IWRES) \[[@CR20]\]. Observations with \|CWRES\| \> 6 or \|IWRES\| \> 6 were flagged as outliers.

We evaluated the influence of a posteriori outliers by comparing estimates of the key model parameters (e.g. systemic clearance \[CL\]) from model fitting on data with and without outliers. The outliers were considered influential if key parameter estimates differed by \> 15%. If outliers were influential, we performed subsequent model development with and without outlying observations.

### Data Analysis Plan {#Sec9}

The population PK analysis proceeded in stages that consisted of adding new data (e.g. by study or administration route) to evaluate changes in PK parameter estimates and ensure adequate pooling of data. First, PK data from early stage studies with intravenous benralizumab were modeled. We then added PK data corresponding to subcutaneous administration for the assessment of absorption rate and absolute bioavailability. Data from the SIROCCO, CALIMA, and BISE studies were also included in the meta-analysis and base model development. A demographic covariate analysis was subsequently performed. Next, we used PK data from ZONDA, a phase III OCS-reduction study, for external validation of the final population PK model. Finally, ZONDA data were integrated into the meta-analysis dataset for re-estimation of the structure and variance parameters.

### Modeling Methodology {#Sec10}

Population model development and simulation were performed using NONMEM (version 7.3; ICON Development Solutions, Hanover, MD, USA) \[[@CR20]\]. The planned method of estimating parameters was the first-order conditional estimation with interaction (FOCEI). We generated data summaries and graphical representations using SAS version 9.3, Splus version 8.2 (TIBCO, Palo Alto, CA), or R version 3.1.2 (The R Foundation for Statistical Computing, Vienna, Austria).

Model development was based on successful minimization and assessment of standard goodness-of-fit (GOF) plots. In addition, we assessed the stability of the models throughout the development process. The covariance matrix of estimates was inspected to verify that extreme pairwise correlations (*p *\> 0.95) of the parameter estimates were not encountered. During model development, if convergence or covariance estimation problems occurred, ad hoc NONMEM runs were performed to evaluate the nature of the ill-conditioning.

### Structural PK Model {#Sec11}

Benralizumab PK data were initially fitted using a two-compartment model with first-order absorption from the subcutaneous dosing site and first-order elimination from the central compartment, based on a previous population PK analysis of data from early phase studies \[[@CR10]\]. The model was parameterized using bioavailability (*F*~1~) fraction, an apparent absorption rate constant (*k*~a~), systemic CL, central volume of distribution (*V*~c~), intercompartmental CL (*Q*), and peripheral volume of distribution (*V*~p~) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Schematic of the population PK model structure. *CL* clearance, *F*~*1*~ bioavailability, *IV* intravenous, *k*~a~ absorption rate constant, *PK* pharmacokinetic, *Q* intercompartmental clearance, *SC* subcutaneous, *V*~c~ central volume of distribution*, V*~p~ peripheral volume of distribution
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### Stochastic PK Model {#Sec12}

The population PK base model consisted of the structural model, between-patient variability (BPV), and residual error model. Interoccasion variability (IOV) was also evaluated. We performed population analysis to determine a parsimonious and stable model that described the data adequately.

The BPV model is described in Eq. ([1](#Equ1){ref-type=""}). The initial residual error model contained a proportional component and an additive component (Eq. [2](#Equ2){ref-type=""}):$$\documentclass[12pt]{minimal}
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### Covariate Model-Building Procedure {#Sec13}

We selected demographic covariates based on clinical judgment, mechanistic plausibility, and prior knowledge. PK parameter--covariate relationships were initially examined graphically to identify any potential relationships to be assessed in subsequent modeling.

A full-model approach was employed by simultaneously including into the base PK model all covariates demonstrating a trend in their empirical Bayes estimates of the random effects *η*. We modeled the relationship between continuous covariates and PK parameters using power functions, with the covariate *X* normalized by a reference value *X*~ref~ (70 kg for body weight and approximate median for other covariates). The continuous covariate effect on a PK parameter *P* with log-based parameterization is presented in Eq. ([3](#Equ3){ref-type=""}):$$\documentclass[12pt]{minimal}
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The categorical covariates were modeled using fractional change functions of the covariate factor (Eq. [4](#Equ4){ref-type=""}, with log-based parameterization):$$\documentclass[12pt]{minimal}
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                \begin{document}$$ { \ln }P = \theta^{P} + \theta^{Y} \cdot Y, $$\end{document}$$where *θ*^*Y*^ represents the logarithm of the fractional change to the PK parameter *P* when factor *Y *= 1.

The effects of injection site (arm, stomach, or thigh) and antidrug antibody (ADA) status could not be evaluated by covariate *η* plots and were evaluated in an ad hoc fashion following formal covariate analysis.

### Finalization of the Population PK Model {#Sec14}

We developed the final model by incorporating the effect of relevant covariates on key structural model parameters of the base model.

Because of the extensive PK data, long model run times, and the limitation of the backward elimination procedure only providing one specified path through the model space, the Wald's Approximation Method (WAM) \[[@CR21]\] was used to identify a subset of reduced PK models relative to the PK full model. The WAM procedure ranked all 2^*k*^ possible submodels derived from the presence or absence of *k* covariate parameters in the full model. The WAM algorithm approximates the log-likelihood surface by a quadratic equation in the covariate effects based on the estimates and asymptotic variance--covariance matrix of the estimates from the full model fit. Typically, maximizing Schwarz's Bayesian Criterion is used as a penalty to rank all 2^*k*^ possible models. In this case, the penalty of 10.83 corresponding to a *p* value cut-off of 0.001 from a Chi-square distribution with 1 degree of freedom was used as a penalty to the likelihood ratio test. The final parsimonious model was selected based on NONMEM rankings.

Assessment of the GOF plots, visual predictive checks (VPCs), and external model validation were conducted to evaluate the performance of the final PK model.

Results {#Sec15}
=======

Data Summary {#Sec16}
------------

A total of 3533 patients with asthma were included in the initial dataset (excluding ZONDA). PK data from 1227 patients who received placebo, and samples obtained prior to the first dose of benralizumab, were excluded from the analysis. Because of the low and variable PK concentrations in patients with asthma receiving benralizumab 2 mg subcutaneously in study NCT01238861, the 589 samples from these 81 patients were excluded from population modeling. Missing PK concentrations from 17 patients and 75 PK concentrations with unrealistic values or unclear dosing records were also excluded.

The initial population PK model (excluding ZONDA) was supported by 14,106 quantifiable benralizumab concentrations from 2174 patients with asthma. The majority of patients received a subcutaneous injection at 30 mg (80%) or 100 mg (11%). Pivotal phase III studies (SIROCCO, CALIMA) contributed the most observations, followed by the phase IIb study NCT01238861. In addition, ZONDA contributed 832 quantifiable serum benralizumab concentrations from 143 patients for external model validation.

The baseline continuous and categorical covariates that were investigated in the population PK model included body weight, age, age group (adult or adolescent), race, smoking status, hepatic markers (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and total bilirubin \[TBL\]), creatine CL (CRCL), albumin, immunogenicity status, and concomitant use of montelukast, paracetamol, proton pump inhibitors, macrolides, or theophylline/aminophylline (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 2Summary of continuous covariatesStudy (phase)NCT00512486 (I)NCT00659659 (I)NCT00768079 (II)NCT00768079 (IIa)NCT01238861^a^ (IIb)SIROCCO \[NCT01928771\] (III)CALIMA \[NCT01914757\] (III)ZONDA\
\[NCT02075255\] (III)BISE\
\[NCT02322775\]\
(III)TotalAge, years *N*301772193037798511431032317 Mean (SD)24.73 (6.36)38.88 (13.81)36.35 (10.8)45.63 (12.76)48.5 (12.4)48.97 (14)49.65 (13.8)51.47 (11.11)48.5 (14.22)48.48 (13.88) Median (min, max)22 (18, 41)37 (20, 62)37.5 (19, 60)44 (27, 69)51 (19, 75)51 (12, 75)51 (12, 75)52 (20, 75)51 (18, 75)50 (12, 75)Albumin, g/L *N*30170193031690103497 Mean (SD)40.93 (3.34)45 (2.92)--45.26 (2.47)44.39 (2.63)43.31 (2.57)44 (2.92)--43.88 (3.04)44.09 (2.89) Median (min, max)41 (35, 47)45 (39, 49)--45 (41, 51)45 (37, 52)43 (38, 47)44 (41, 50)--44 (37, 52)44 (35, 52)ALP, ukat/L *N*3007003037798501431032278 Mean (SD)1.07 (0.24)--1.29 (0.37)--1.25 (0.39)1.26 (0.58)1.26 (0.57)1.12 (0.33)1.14 (0.29)1.24 (0.52) Median (min, max)1.05 (0.68, 1.6)--1.33 (0.22, 2.33)--1.2 (0.53, 3.85)1.17 (0.38, 7.75)1.18 (0.37, 8.9)1.07 (0.53, 2.63)1.1 (0.6, 2.07)1.17 (0.22, 8.9)ALT, ukat/L *N*301769193037798501431032313 Mean (SD)0.44 (0.19)0.62 (0.55)0.41 (0.25)0.39 (0.15)0.4 (0.24)0.37 (0.21)0.39 (0.3)0.4 (0.26)0.36 (0.18)0.39 (0.25) Median (min, max)0.42 (0.15, 1.03)0.42 (0.15, 2.05)0.33 (0.15, 1.62)0.37 (0.2, 0.85)0.33 (0.07, 2.33)0.32 (0.08, 2)0.32 (0.12, 5.95)0.33 (0.1, 2.32)0.32 (0.13, 0.98)0.33 (0.07, 5.95)AST, ukat/L*N*301769193037798501431032313Mean (SD)0.36 (0.08)0.61 (0.63)0.35 (0.16)0.39 (0.1)0.36 (0.13)0.34 (0.12)0.36 (0.15)0.33 (0.15)0.33 (0.1)0.35 (0.15)Median (min, max)0.36 (0.23, 0.57)0.4 (0.27, 2.92)0.32 (0.17, 1.08)0.4 (0.22, 0.58)0.33 (0.17, 1.23)0.32 (0.15, 1.3)0.33 (0.15, 2.67)0.32 (0.08, 1.45)0.32 (0.15, 0.72)0.32 (0.08, 2.92)Body weight, kg *N*301772193037788511431032316 Mean (SD)73.65 (11.88)79.66 (16.62)85.45 (22.93)84.7 (20.07)77.88 (17.31)77.71 (19.53)78.72 (19.96)84.41 (20.47)85.74 (21.85)79.14 (19.74) Median (min, max)70.8 (52.9, 108)78.2 (57.5, 109)80.9 (42, 136.1)83.5 (51.71, 130.64)75 (46, 136)76 (40, 194.5)77 (41, 204.4)80.2 (47, 155.2)80 (45, 183.9)77 (40, 204.4)CRCL, mL/min *N*301770193037788501431032313 Mean (SD)115.38 (24.8)115.57 (33.09)123.27 (39.54)111.76 (39.59)111.48 (33.94)110.49 (35.5)110.22 (37.74)111.89 (33.09)118.46 (37.19)111.46 (36.15) Median (min, max)113.78 (67.89, 196.67)115.49 (62.46, 172.84)120.84 (45.62, 236.65)98.4 (64.85, 211.52)106.72 (41.47, 265.31)104.19 (39.66, 349.17)103.76 (2.41, 334.47)112.34 (31.8, 203.79)113.36 (65.9, 276.34)105.71 (2.41, 349.17)Estimated GFR, mL/min/1.73 m^2^ *N*301770193037798501431032314 Mean (SD)88.85 (28.99)90.18 (28.07)101.25 (35.49)88.17 (35.74)99.98 (31.72)99.76 (34.11)96.66 (32.96)90.01 (30.18)93.06 (30.97)97.49 (33.06) Median (min, max)93.04 (42.32, 142.4)85.53 (54.75, 151.64)96.23 (34.27, 199.01)77.89 (37.4, 153.01)102.77 (34.96, 196.66)100.85 (38.35, 251.62)96.74 (0.87, 242.81)89.84 (26.07, 169.43)93.55 (47.67, 191.85)97.78 (0.87, 251.62)Total bilirubin, µmol/L *N*301770193037798501431032314 Mean (SD)10.83 (3.77)11.47 (6.7)6.72 (4.38)7.56 (3.29)8.14 (4.1)8.22 (4.19)7.76 (4.05)7.9 (4.51)7.54 (4.42)8 (4.2) Median (min, max)10.26 (3.42, 20.52)11.97 (3.42, 29.07)5.13 (1.71, 25.65)6.84 (3.42, 17.1)6.84 (1.71, 30.78)7 (1.71, 31)7 (1.71, 27.36)7 (1.71, 36)7 (1.71, 34)7 (1.71, 36)*ALP* alkaline phosphatase, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *CRCL* creatinine clearance (calculated using the Cockcroft--Gault equation), *GFR* glomerular filtration rate, *max* maximum, *min* minimum, *PK* pharmacokinetic, *Q4W* every 4 weeks, *SD* standard deviation^a^PK data for the subcutaneous 2-mg Q4W dosage from study NCT01238861 were initially included in the analysis data file for evaluation in base model development; however, these data were later excluded from the population PK analysis because of low and variable PK observations, and are hence not reportedTable 3Summary of categorical covariatesStudy (phase)NCT00512486 (I)NCT00659659 (I)NCT00768079 (II)NCT00768079 (IIa)NCT01238861^a^ (IIb)SIROCCO \[NCT01928771\] (III)CALIMA \[NCT01914757\] (III)ZONDA \[NCT02075255\] (III)BISE \[NCT02322775\] (III)Total *N* (%)30 (1.29)17 (0.73)72 (3.11)19 (0.82)303 (13.08)779 (33.62)851 (36.73)143 (6.17)103 (4.45)2317 (100)Age category \[*n* (%)\] Adolescent0000029 (3.72)28 (3.29)0057 (2.46) Adult30 (100)17 (100)72 (100)19 (100)303 (100)750 (96.28)823 (96.71)143 (100)103 (100)2260 (97.54)Race \[*n* (%)\] White29 (96.67)16 (94.12)30 (41.67)16 (84.21)211 (69.64)555 (71.25)716 (84.14)133 (93.01)95 (92.23)1801 (77.73) African-American01 (5.88)38 (52.78)3 (15.79)13 (4.29)29 (3.72)23 (2.70)1 (0.7)7 (6.80)115 (4.96) Asian001 (1.39)03 (0.99)104 (13.35)110 (12.93)8 (5.59)1 (0.97)227 (9.8) Other1 (3.3)03 (4.17)076 (25.08)91 (11.68)2 (0.24)1 (0.7)0174 (7.51)Sex \[*n* (%)\] Male15 (50.00)7 (41.18)25 (34.72)8 (42.11)97 (32.01)267 (34.27)316 (37.13)57 (39.86)43 (41.75)835 (36.04) Female15 (50.00)10 (58.82)47 (65.28)11 (57.89)206 (67.99)512 (65.73)535 (62.87)86 (60.14)60 (58.25)1482 (63.96)Immunogenicity status (ADA) \[*n* (%)\] Positive7 (23.33)4 (23.53)7 (9.72)4 (21.05)84 (27.72)104 (13.35)126 (14.81)12 (8.39)14 (13.59)362 (15.62) Negative23 (76.67)13 (76.47)65 (90.28)15 (78.95)219 (72.28)675 (86.65)725 (85.19)131 (91.61)89 (86.41)1955 (84.38)Smoking history \[*n* (%)\] Current smoker0021 (29.17)001 (0.13)3 (0.35)01 (0.97)26 (1.12) Former smoker02 (11.76)18 (25.00)5 (26.32)49 (16.17)151 (19.38)190 (22.33)29 (20.28)17 (16.50)461 (19.9) Never smoked07 (41.18)33 (45.83)14 (73.68)254 (83.83)627 (80.49)658 (77.32)114 (79.72)85 (82.52)1792 (77.34) Unknown30 (100)8 (47.06)000000038 (1.75)Concomitant montelukast use \[*n* (%)\] Yes01 (5.88)2 (2.78)01 (0.33)278 (35.69)257 (30.20)55 (38.46)7 (6.80)601 (25.94) No30 (100)16 (94.12)70 (97.22)19 (100)302 (99.67)501 (64.31)594 (69.80)88 (61.54)96 (93.20)1716 (74.06)Concomitant paracetamol use \[*n* (%)\] Yes8 (26.67)4 (23.53)6 (8.33)1 (5.26)8 (2.64)36 (4.62)30 (3.53)8 (5.59)5 (4.85)106 (4.57) No22 (73.33)13 (76.47)66 (91.67)18 (94.74)295 (97.36)743 (95.38)821 (96.47)135 (94.41)98 (95.15)2211 (95.43)Concomitant PPI use \[*n* (%)\] Yes01 (5.88)6 (8.33)2 (10.53)37 (12.21)139 (17.84)136 (15.98)49 (34.27)12 (11.65)382 (16.49) No30 (100)16 (94.12)66 (91.67)17 (89.47)266 (87.79)640 (82.16)715 (84.02)94 (65.73)91 (88.35)1935 (83.51)Concomitant macrolides use \[*n* (%)\] Yes002 (2.78)01 (0.33)4 (0.51)4 (0.47)1 (0.7)012 (0.52) No30 (100)17 (100)70 (97.22)19 (100)302 (99.67)775 (99.49)847 (99.53)142 (99.3)103 (100)2305 (99.48)Concomitant theophylline/aminophylline use \[*n* (%)\] Yes0000084 (10.78)107 (12.57)21 (14.69)0212 (9.15) No30 (100)17 (100)72 (100)19 (100)303 (100)695 (89.22)744 (87.43)122 (85.31)103 (100)2105 (90.85)*ADA* antidrug antibody, *PK* pharmacokinetic, *PPI* proton pump inhibitors, *Q4W* every 4 weeks^a^PK data for the 2-mg Q4W subcutaneous dosage from study NCT01238861 were initially included in the analysis data file for evaluation in base model development; however, these data were later excluded from the population PK analysis because of low and variable PK observations, and are hence not reported

Structure PK Model Development {#Sec17}
------------------------------

Table [4](#Tab4){ref-type="table"} presents the key steps in the development of the benralizumab population PK model. Model development was initiated with the analysis of intravenous data. The iterative two-stage (ITS)/stochastic approximation expectation maximization (SAEM)/importance sampling (IMP) methods, as implemented in NONMEM, were adopted, and the PK concentration data were log-transformed to facilitate model development. A log-normal residual error structure was used to increase the influence of lesser concentrations on the estimates.Table 4Key model development stepsModel no.DescriptionDatasetOBJΔOBJComparator1Two-compartment modelIV data only− 878.82NANA2Two-compartment PK, first-order SC absorptionIV + SC^a^− 212.22NANA3Two-compartment PK, first-order SC absorption, separated *F*~1~ for the phase IIb study NCT01238861IV + SC^a^− 455.42− 243.20Model 24Separated *F*~1~ and residual error for the phase IIb study NCT01238861IV + SC^a^− 613.09− 157.67Model 35Further separated residual error for phase III studies, base modelIV + SC^a^− 834.038− 215.66Model 46Base model + body weight effects on CL, *V*~c~, and *V*~p~IV + SC^a^− 1324.92− 496.17Model 57Added ADA effect on CLIV + SC^a^− 5547.03− 4222.1Model 68Fixed IIV(*Q*) = 0.008; final modelIV + SC^a^− 5549.282.25Model 79Including ZONDA; final updated modelIV + SC (including ZONDA)− 6506.498NANA*ADA* antidrug antibody, *CL* clearance, *F*~1~ bioavailability, *IV* intravenous, *NA* not applicable, *OBJ* objective function, *PK* pharmacokinetics, *SC* subcutaneous, *V*~c~ central volume of distribution, *V*~p~ peripheral volume of distribution, *Δ* indicates change in^a^Does not include data from ZONDA

The PK model was subsequently expanded to incorporate the subcutaneous route of administration, which was adequately described by a first-order absorption process. Exponential parameterization performed slightly better than a logit transformation for absolute bioavailability (*F*~1~). The estimated *F*~1~ and BPV of *F*~1~ for study NCT01238861 were different from the other studies. In addition, the variance of residual error (*σ*^2^) was different for early stage studies (phase I--IIa, studies NCT00512486, NCT00659659, NCT00768079 and NCT00783289), phase IIb (NCT01238861), and phase III studies (SIROCCO, CALIMA, and BISE).

Covariate Analysis {#Sec18}
------------------

Body weight was identified as a relevant covariate, with significant effects on CL, *V*~c~, and *V*~p~ (Model 6, Table [4](#Tab4){ref-type="table"}). In addition, the inclusion of ADA status on CL resulted in a \> 4000-unit reduction in objective function (OBJ) value (Model 7, Table [4](#Tab4){ref-type="table"}).

The effects of other covariates were evaluated using plots of empirical Bayes estimates (i.e. ETA plots). No real trends in the ETA plots were noted, except a modest correlation between *η*~CL~ and CRCL. Using the WAM algorithm, the effect of sex, race---Asian, and race---black on CL was \< 10%. The effect of race---other on CL was 19%, but the 90% confidence interval precluded a meaningful effect. These covariate effects were also considered nonmeaningful for *V*~c~. The statistical detection of such nonmeaningful effects likely stemmed from the large sample size in the dataset.

The effect of CRCL on CL was statistically significant; an estimate of 0 was not precluded. There was a general trend of increasing effect on CL with greater CRCL. However, the apparent correlation of CRCL and benralizumab CL could be an artifact as both were influenced by body weight (heavier patients tended to have greater CRCL and CL). A posterior ad hoc analysis confirmed that renal function (estimated glomerular filtration rate \[eGFR\]) did not influence benralizumab CL.

Hepatic function markers (ALP, ALT, AST, and TBL), concomitant medications, or baseline eosinophil count had no impact on the PK of benralizumab.

External Model Validation {#Sec19}
-------------------------

The final model was used to predict benralizumab PK profiles from ZONDA. The model-predicted PK exposures, represented by 90% percentile intervals (PIs), were compared with observed serum concentrations of benralizumab in ZONDA. Figure [2](#Fig2){ref-type="fig"} presents results of the VPCs, grouped by regimen and quantile of body weight. Observed PK profiles in ZONDA were mostly within the PIs across all weight ranges, indicating that the model was adequate in predicting ZONDA benralizumab exposures.Fig. 2Model external validation using PK data from study ZONDA. Visual prediction checks, grouped by regimen and body weight quantile. *Shaded area* represents the 90% PI of model-predicted PK exposure. *Gray points* indicate observed serum concentrations of benralizumab in ZONDA, and *blue boxes* indicate the observed medians. *\@4W + 4W + Q8W* every 4 weeks for the first three doses, followed by every 8 weeks, *Conc.* concentration, *PI* prediction interval, *PK* pharmacokinetic, *Q4W* every 4 weeks, *SC* subcutaneous

Final Updated Population PK Model {#Sec20}
---------------------------------

ZONDA data were appended to the analysis dataset that contained PK data from three phase III studies (SIROCCO, CALIMA, and BISE) and five early phase studies. The PK model was refitted to the pooled 14,918 observations for 2317 patients from all nine clinical studies. Table [5](#Tab5){ref-type="table"} presents the structure and variance parameter estimates. A VPC was performed for the final updated model, which adequately captured the population concentration-time profile of benralizumab (Fig. [3](#Fig3){ref-type="fig"}).Table 5Pharmacokinetic parameter estimates for the base and final updated modelsParameterBase model (Model 5)Final updated model (Model 9)Estimate90% CIEstimate90% CICL, L/day0.3570.341--0.3740.2910.28--0.302Body weight on CL, power0.8070.751--0.864ADAs on CL, fraction2.242.18--2.3*V*~c~, L3.823.56--4.103.132.97--3.31Body weight on *V*~c~, power0.8030.627--0.979*Q*, L/day1.460.899--2.380.7380.679--0.803Body weight on *Q*, power0--*V*~p~, L2.772.49--3.092.522.34--2.71Body weight on *V*~p~, power0.5280.351--0.706*k*~a~, half-life; days3.352.76--4.073.543.15--3.99*F*0.6710.637--0.7070.5890.565--0.614Change in *F* with study CP220, fraction0.5690.521--0.6220.4900.461--0.522IIV *η*~CL~, %CV29.527.6--31.324.222.6--25.6 *η*~Vc~, %CV29.924.6--34.524.420.7--27.6 *η*~Q~, %CV132101--1578.94-- *η*~Vp~, %CV37.329.6--43.644.740.5--48.5 *η*~ka\ (half-life)~, %CV68.157.6--77.283.175.5--90.1 *η*~F~, %CV11.94.19--16.317.113.5--20 *η*~F(study\ CP220)~, %CV61.653.4--68.735.028.8--40.2Residual variability Proportional error, %CV28.126.5--29.725.023.8--26.1 Proportional error (study CP220), %CV57.955.5--60.154.552.5--56.3 Proportional error (studies SIROCCO, CALIMA, ZONDA^a^, BISE), %CV46.045.4--46.736.736.2--37.1*ADAs* antidrug antibodies, *CI* confidence interval, *CL* clearance, *CV* coefficient of variation, *F* bioavailability, *IIV* interindividual variability, *k*~a~ absorption rate constant, *Q* intercompartmental clearance, *V*~c~ central volume of distribution, *V*~p~ peripheral volume of distribution^a^ZONDA was not included in the base modelFig. 3Visual predictive check of the final updated pharmacokinetic model. Study 17 = SIROCCO; Study 18 = CALIMA. *\@4W + Q8W* every 4 weeks for the first three doses, followed by every 8 weeks, *Conc.* concentration, *IV* intravenous, *PI* prediction interval, *Q4W* every 4 weeks

Figure [4](#Fig4){ref-type="fig"} illustrates the effects of body weight and ADA on the PK of benralizumab. Benralizumab CL and volumes of distribution were greater for patients with greater body weight. The presence of ADA was associated with elevated CL of benralizumab.Fig. 4Effects of body weight and ADA on the PK of benralizumab for patients with asthma. *Closed circles* represent CL in patients when ADA results were negative; *open circles* represent CL in patients when ADA results were positive. *Red lines* represent prediction curves \[CL·(body weight/70)^0.807^\], and *blue lines* represent locally weighted scatterplot smoothing (LOWESS). *ADA* antidrug antibodies, *CL* clearance, *PK* pharmacokinetics

During model development, CRCL had a statistically significant effect on CL. The renal function classification based on the CRCL and eGFR values was performed according to the FDA Guidance for Industry \[[@CR22]\]. Despite the apparent trend of increasing benralizumab CL with greater CRCL (Fig. [5](#Fig5){ref-type="fig"}a), there was no correlation of CL with eGFR (Fig. [5](#Fig5){ref-type="fig"}b). Baseline blood eosinophil count had no effect on benralizumab CL. Figure [5](#Fig5){ref-type="fig"}c shows a box plot comparing CL for patients with asthma by baseline blood eosinophil counts (\< 150, 150--299, 300--449, and \> 450 cells/µL).Fig. 5No clinically meaningful effect of renal function or baseline eosinophil count on benralizumab CL. CLCR and eGFR grouped by values associated with levels of renal functions. *CL* clearance, *CRCL* creatinine clearance, *eGFR* estimated glomerular filtration rate

Subcutaneous benralizumab was administrated exclusively in the upper arm in many early stage studies; however, in later stage studies, benralizumab was also administered in the abdomen and thigh. An ad hoc analysis demonstrated no clinically relevant effect of anatomical injection site on benralizumab bioavailability.

Discussion {#Sec21}
==========

Treatment with benralizumab, a potent anti-eosinophil mAb, leads to nearly complete depletion of blood and airway eosinophils for patients with mild to severe asthma following single or repeated dosing \[[@CR5], [@CR6], [@CR8]\]. The phase III program of benralizumab demonstrated a significant and clinically relevant reduction in asthma exacerbations, improvement in lung functions, and reduced asthma symptoms and OCS use for patients with severe asthma compared with placebo. Benralizumab is approved as an add-on maintenance treatment for patients ≥ 12 years of age with severe asthma and an eosinophilic phenotype \[[@CR6]--[@CR8]\]. The PK of benralizumab have been demonstrated to be dose-proportional at dosages of 0.03--3 mg/kg \[[@CR16]\].

The PK of benralizumab were evaluated in nine clinical studies for adults and adolescents with severe asthma. Benralizumab dosage, dosing intervals, administration routes, and treatment durations differed across studies. The weight-based dosing method was used in early stage studies, whereas fixed subcutaneous doses of benralizumab were administered to patients in phase II and III studies. In addition, except for in the first-in-human study NCT00512486, the PK sampling schedule was limited or sparse (Table [1](#Tab1){ref-type="table"}). To fully characterize the PK properties of benralizumab and to assess the clinical relevance of demographic covariate effects, PK data from these studies were pooled for a population meta-analysis.

A total of 14,983 quantifiable PK observations from 2317 benralizumab-treated patients were included in the population analysis dataset. Data from 81 patients who received benralizumab 2 mg every 8 weeks in study NCT01238861 (3.4% of all benralizumab-treated patients) were excluded as the majority of observed trough PK concentrations were below the limit of quantification (BLQ), and the dosage was 15-fold less than the 30-mg therapeutic dosage evaluated in the phase III program. In addition, as \< 10% of data records were BLQ, imputing methods for BLQ observations were not implemented \[[@CR23]\]. Of four phase III studies in the population modeling dataset, ZONDA was the last to complete. Therefore, PK data from ZONDA were used for model external validation \[[@CR24]\].

Although the FOCEI method, as implemented in NONMEM, was initially planned for the pharmacometrics assessment, expectation maximization (EM) methods were instead used to facilitate PK model development. Given the heterogeneity of data across studies and the sparse PK sampling schedule in late-stage studies, the FOCEI method occasionally led to convergence difficulties. Conversely, the SAEM method in conjunction with IMP proved to be robust and flexible. At each iteration, the Markov Chain Monte Carlo SAEM led toward the maximum of exact likelihood. The OBJ value was obtained by IMP at the final parameter values. The final PK model developed with EM methods (prior to external validation with ZONDA data) was rerun with the FOCEI method, and OBJ values from the two methods were comparable: the OBJ of FOCEI was 0.45 units greater than SAEM/IMP. In this analysis, the reported OBJ and parameter estimates are all based on EM methods.

The PK of benralizumab were dose-proportional across a wide range of dosages investigated in these studies and were adequately described by a two-compartment model with first-order elimination from the central compartment and a first-order absorption process from the subcutaneous dosing site. From population modeling, there was no evidence of an IL-5R--mediated nonlinear elimination pathway because of the rapid depletion of circulating IL-5R--expressing eosinophils following benralizumab administration. In addition, given the slow absorption of immunoglobulin G (IgG) from the subcutaneous dosing site and the limited PK sampling schedule in phase II and III studies, delayed absorption or logit-transformed bioavailability were not supported by available data.

The absorption of benralizumab was slow following subcutaneous administration, with an estimated absorption half-life of 3.5 days for patients with asthma (Table [5](#Tab5){ref-type="table"}). The estimated absolute bioavailability of benralizumab from population modeling was 59%, which is in line with other approved therapeutic mAbs and Fc-fusion proteins \[[@CR25], [@CR26]\]. In phase II studies, subcutaneous benralizumab was administered in the upper arm of each patient; however, for each patient enrolled in the phase III program, subcutaneous benralizumab or placebo was administered in different anatomical sites (upper arm, abdomen, and thigh) following a prespecified rotation sequence \[[@CR11], [@CR12]\]. The estimated subcutaneous bioavailability of benralizumab administered to the stomach or thigh was approximately 9% greater than the bioavailability after administration to the upper arm; however, the magnitude of the effect was not considered clinically relevant. This result could support flexibility in the choice of an injection site for subcutaneous administration of benralizumab. Definitive assessment of relative bioavailability of benralizumab administered to different anatomic sites requires a single-dose PK study in healthy volunteers, with a more intensive sampling schedule (AMES study; NCT02968914).

As with other therapeutic IgGs, benralizumab is primarily eliminated through the reticuloendothelial system by the widely expressed proteolytic enzyme. From population modeling, the estimated typical CL for a 70-kg patient was 0.291 L/day. Distribution of IgG and other recombinant proteins is usually restricted to extracellular fluid. The estimated *V*~c~ and *V*~p~ for benralizumab were 3.13 L and 2.52 L, respectively, which is typical for IgG. The PK elimination half-life of benralizumab is approximately 15.5 days for patients with asthma.

Body weight was identified as a relevant covariate for CL, *V*~c~, and *V*~p~. As for other therapeutic mAbs, benralizumab CL increased with body weight. The effect of body weight was nearly allometric for benralizumab CL (power parameter estimate of 0.807). The allometric exponent for the effect of body weight was estimated as 0.803 for *V*~c~ and 0.528 for *V*~p~; however, body weight had no impact on efficacy or eosinophil depletion \[[@CR15]\].

Benralizumab was immunogenic in a small subset of patients. The development of ADAs was associated with a reduction in PK exposure. From the demographic covariate analysis, ADA status was the most influential covariate effecting benralizumab CL, resulting in a \> 4000-unit reduction in NONMEM OBJ value. Although the presence of ADAs was related to a marked increase (124%) of benralizumab CL, it had no impact on the primary and key secondary efficacy endpoints in benralizumab phase III trials \[[@CR15], [@CR27]\]. The selection of 30 mg every 8 weeks as the therapeutic dosage greatly reduced the impact of PK variability on efficacy outcome \[[@CR11], [@CR12]\].

Benralizumab treatment results in the rapid, near-complete depletion of blood eosinophil counts \[[@CR5]\]. The lack of any trend in CL across groups suggests that eosinophil count does not have a meaningful impact on benralizumab CL, as evidenced by the absence of a nonlinear IL-5R--mediated elimination pathway of benralizumab in humans.

There was a general trend of increasing benralizumab CL with greater CRCL; however, calculated CRCL was proportional to body weight, whereas body weight allometrically affected benralizumab CL. A post hoc analysis using eGFR as a marker demonstrated that renal function had no effect on the PK of benralizumab.

IgG mAbs are not primarily cleared via the hepatic pathway; therefore, change in hepatic function is not expected to influence benralizumab CL. In this population analysis, no liver function markers (ALT, AST, and TBL) were identified as relevant PK covariates.

The effects of sex and race on benralizumab were considered insignificant. The statistical detection of such insignificant effects may stem from the large sample size of the dataset. Benralizumab mean exposure decreased slightly from adolescents (12--17 years of age) to older adults (65--75 years of age). The terminal half-life of benralizumab increased slightly with age, with median estimates of approximately 14 days in adolescents, 15 days in adults (18--64 years of age), and 17 days in older adults.

Benralizumab selectively targets and binds IL-5Rα, which is selectively expressed on eosinophils and basophils. IL-5Rα is not expressed on hepatocytes, and treatment with benralizumab has no identified effect on other circulating cytokines, except for IL-5 and the eosinophil chemokines eotaxin-1 and eotaxin-2. From population analysis, commonly used small-molecule drugs (montelukast, paracetamol, proton pump inhibitors, macrolides, and theophylline/aminophylline) had no effect on benralizumab CL. Together, these data indicate that the potential risk of interactions between benralizumab and other drugs is low.

Conclusions {#Sec22}
===========

Benralizumab PK data for adult and adolescent patients with asthma were pooled from nine phase I--III clinical trials and simultaneously modeled using a population approach. The PK of benralizumab are dose-proportional across a wide dosage range. The estimated disposition parameter values of benralizumab are typical for a human IgG. Body weight and ADA status were identified as relevant PK covariates; however, further exposure--response analysis has demonstrated that neither impacts benralizumab efficacy at the 30-mg every 8 weeks dosage. Baseline eosinophil count, hepatic and renal functions, anatomical subcutaneous injection site, and commonly used small-molecule drugs had no impact on the PK of benralizumab.
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